What’s News in Earnings: How Big Pharma Is Expanding the GLP-1 Market

单集文稿 ...

• 00:00

  It's time to get Brex AF, a gen tech finance that eliminates manual work and puts you in control.

• 00:04

  Learn more at brex. com slash AF.

• 00:10

  Hey, listeners, it's Friday, May 8th.

• 00:12

  I'm David Wehner for The Wall Street Journal,

• 00:14

  and this is What 's News in Earnings, our look at some of the biggest themes standing out this earnings season.

• 00:20

  The weight loss drug market is still growing faster than Wall Street expects.

• 00:25

  Industry leader Eli Lilly last week reported results that blew past analyst estimates,

• 00:30

  and the company raised its forecast for sales this year.

• 00:33

  And that was mostly because of consumer demand for its GLP-1 injections.

• 00:38

  Meanwhile, Novo Nordisk said the prescriptions for its new Wagovi pill are off to a strong start.

• 00:44

  That showed that people around the world just ca n't get enough of weight loss drugs,

• 00:48

  with growing demand for the pills as well as the injectables.

• 00:53

  Elsewhere in pharma, companies are mostly delivering positive results,

• 00:57

  with Merck, Bristol-Myers Squibb, and AbbVie all posting earnings beats.

• 01:02

  But investors are still debating the durability of their long-term growth.

• 01:13

  We're joined now by Wall Street Journal reporter Peter Loftus, who covers the pharmaceutical industry.

• 01:19

  Peter, where do things stand in the whole pill versus pill battle?

• 01:23

  Basically, Novo's oral Wagovi going up against Lilly's Fondeo.

• 01:27

  Is there a clear winner emerging, or is it still too early to call?

• 01:32

  Right now, you'd have to say Novo Nordisk has the edge.

• 全部文稿